Abevmy®

ACTIVE PRINCIPLE:
bevacizumab

INDICATION:
Colorectal cancer
Breast cancer
Ovarian cancer
Fallopian tube cancer
peritoneal cancer
Non-small cell lung carcinoma
Renal cell carcinoma
cervical cancer

DATE:
23/02/2024

STATUS:
Authorized